



Post-AGM Presentation

5TH NOVEMBER 2025

Disclaimer



This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

About Rhythm Biosciences



We are committed to saving lives through the evaluation of cancer risk and early detection of cancers



Early detection of cancer gives individuals the best possible opportunity for favorable treatment outcomes.

Addressing large under-served global markets worth >USD\$50bn and heavily supported by public and private health care systems.

geneType™ commercially available now and ColoSTAT® anticipated commercial launch in 2H CY2025.

Patent protected, fully characterised proteomic, genomic technology that can be readily adopted in routine laboratories.

A valuable development pipeline of high quality, impactful cancer risk assessment and detection products.

Rhythm Bioscience: An attractive investment opportunity



Overview

Rhythm's mission is to detect cancer earlier and reduce the burden of cancer. We are developing and selling proprietary, high value products and services designed to detect cancer earlier.

Growth

Rhythm is solving an important clinical and economic problem. We are preparing for rapid global commercial growth.

Reasons to Invest


1. Multi-product portfolio.
2. Addressing a significant TAM.
3. Poised for revenue growth acceleration.

When diagnosed early, cancer can be successfully treated


Disease stage for colorectal cancer diagnosis is the key predictor of survival




Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed in:



Disease treatment costs increase with later stage#




Missed detection of early-stage CRC results in poor survival rates



5-year survival rates in patients with CRC in US, UK and Australia

Detecting cancer earlier and maintaining wellness

The power of the combination of the Rhythm capabilities and portfolio



Risk Assessment

Determination
of risk profile.

Personalised management
of health.



Disease Screening

Minimally-invasive detection
of disease.

Early detection of disease.

Clinical Performance across the
continuum of CRC stages I – IV.

A powerful combination enabling:

- Supports preventative measures to maintain wellness.
- Increase the likelihood of earlier disease detection.
- Promote better treatment outcomes for detected disease.
- Potential use in drug clinical studies for patient stratification.
- Potential for development as companion diagnostic tests.

Suitable for 100s millions of individuals/patients globally

Example: geneType™ bowel cancer risk assessment of the general population to help guide usage of ColoSTAT®. Potentially leads to improved screening compliance, earlier disease detection and improved outcomes.

About ColoSTAT®



COLOSTAT®

**A high quality,
affordable blood-
based alternative for
colorectal cancer
detection**



ColoSTAT® has been developed as an alternative blood-based solution for use in the detection of colorectal cancer


A subset of the higher risk population decline the use of stool-based tests

Initial intended use is for higher risk, symptomatic individuals who are seeking an alternative to stool-based testing

The ultimate goal for Rhythm is to develop clinical data to support the use of ColoSTAT® in general screening.

ColoSTAT[®] development history

An extensive clinical evaluation and careful design of a high-quality assay format




ColoSTAT[®] FY26 commercial strategy

Speed-to-market regulatory strategy and capital efficient commercial partnering



ColoSTAT[®] Assay Delivery



Geographical Priorities



Channel Strategy

- Health Care Professionals
- Strategic partners



About Genetype



**A unique, integrated,
personalized cancer risk
assessment platform
leveraging clinical and
genomic information.**



A cancer risk assessment platform designed for sporadic cancer risk


Scope includes 6 cancers with validation data on 100,000s of individuals

Personalised using an individual's clinical history and genomic data

Commercially available as a physician requested test in the USA and Australia now

Genotype FY26 commercial strategy

Genotype FY26 Test Volumes



Oncology Portfolio Focus



- Breast*
- Prostate
- Colorectal*
- Ovarian
- Melanoma
- Pancreatic*

* Rhythm protein biomarker program overlap

Channel Strategy



- Health Care Professionals – B2B
- Strategic partners/ Enterprise accounts - B2B2B


Geographical Priorities



Product launches and upgrades

A diversified mix of development stages and underlying technologies will drive value

New Product Release




Product Upgrade Release

Other R&D:

In silico evaluation of combination proteomic and genomic data sets for lung and CRC detection and risk prediction.

Our combined platforms supports a highly comprehensive product pipeline



	BREAST	PROSTATE	COLORECTAL	OVARIAN	MELANOMA	PANCREATIC	LUNG	GASTRIC	CERVICAL
Risk Assessment	●	●	●	●	●	●	●	●	●
Screening	●	●	●	●	●	●	●	●	●
Triage	●	●	●	●	●	●	●	●	●
Biopsy	●	●	●	●	●	●	●	●	●
Surgical Margins	●	●	●	●	●	●	●	●	●
Drug Management	●	●	●	●	●	●	●	●	●
Monitoring	●	●	●	●	●	●	●	●	●

-  Commercial product
-  Active Development Program
-  Progress made/currently on hold
-  Future opportunity

Upcoming value inflection points

PRODUCT	ITEM	DESCRIPTION	COMPLETION DATE
ColoSTAT®	Final clinical validation	Evaluation of final testing system	Q3 CY 2025
geneType™	geneType™ strategic partnerships	Establishment of key commercial partners	Q3 CY 2025
geneType™	geneType™ menu expansion	Expansion of existing product portfolio	Q4 CY 2025
ColoSTAT®	Commercialisation	ColoSTAT® In House IVD launch subject to NATA review	Q4 CY 2025
ColoSTAT®	Commercialisation & further development strategic partnerships	Establish ColoSTAT® commercialisation and clinical indication expansion partners	Q1 CY 2026
Lung cancer screening assay	Complete pre-clinical data evaluation	Design of assay prototype	Q2 CY 2026



Thank you!

david.atkins@rhythmbio.com

www.rhythmbio.com